Outcome of salvage treatment for recurrent XXXX .

@entity1 @entity2903 @entity2904 @entity463 @entity1349
@entity463 ( @entity463 ) cases recur within a year and almost all cases recur at some point. Standard treatment for recurrent @entity463 has not yet been established. We investigated the outcome of various salvage treatments for recurrent @entity463 . Retrospective analysis was undertaken in 144 @entity1 who received salvage treatment at the time of first progression after maximum debulking surgery followed by concomitant chemoradiotherapy and adjuvant @entity2903 ( @entity2904 ) chemotherapy. The median follow-up period was 18.2 months. We grouped these @entity1 into five groups according to the salvage modalities: Gamma Knife radiosurgery (GKS) group (n=29), @entity2904 group (n=31), GKS+ @entity2904 group (n=28), reoperation group (n=38) and "other treatment" group (n=18). The median time to first progression from initial diagnosis was 8.8 months. The median @entity1349 ( @entity1349 ) of the five different treatment groups; GKS, @entity2904 , GKS+ @entity2904 , reoperation, and "other treatment", was 9.2, 5.6, 15.5, 13.2, and 8.0 months, respectively. Median progression-free survival (PFS) was 3.6, 2.3, 6.0, 4.3, and 2.6 months, respectively. Pairwise comparison of @entity1349 of the GKS+ @entity2904 group with the other groups showed that the @entity1349 of the GKS+ @entity2904 group was significantly better than all others except the reoperation group. Statistically significant prolongation of PFS was observed in the GKS+ @entity2904 group compared with the @entity2904 group and the "other treatment" group. GKS followed by @entity2904 salvage treatment was a good prognostic factor for both PFS and @entity1349 in multivariate analysis. Retrospectively, GKS+ @entity2904 as a salvage treatment, tended to provide a superior survival benefit at the time of recurrence.
